re: Ann: Prima BioMed's CVac granted Fast... Ahjay
I don't see why Fast Track designation should impact the company's cash burn rate. The main component of company expenses is the cost of clinical trials. This would have been proceeding apace, regardless of FT status.
Incidentaly, the story just got picked up by The Australian.
http://www.theaustralian.com.au/news/latest-news/fda-fast-tracks-ovarian-cancer-drug/story-fn3dxity-1226911691287
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $366.9M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 25.0¢ | $537.6K | 2.121M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40101 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 297079 | 7 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |